Selank + Semax
A nootropic research blend pairing the anxiolytic peptide Selank with the cognitive/neuroprotective peptide Semax, both Russian-developed. Each has some human data (mostly Russian trials); the combination itself has not been formally studied.
In plain English
This blend pairs two Russian-developed neuropeptides: Selank, studied as an anti-anxiety agent, and Semax, studied for cognition, focus, and neuroprotection (including in stroke). The idea is to combine calm (Selank) with focus (Semax). Both peptides have more human data than most research peptides — but almost entirely from Russian clinical studies, where they are actually approved and prescribed; neither is FDA-approved in the US. There are no formal trials of the two used together, so the combination is an extrapolation from each peptide's individual profile.
What it is
A combination of Selank (a synthetic analog of the immunomodulatory peptide tuftsin) and Semax (a synthetic fragment related to ACTH(4-10)). Both are heptapeptide-class neuropeptides developed in Russia, where they are registered medicines; in the US they are sold only as research peptides.
Mechanism (summary)
Selank is associated with modulation of GABA/serotonergic tone, BDNF, and immune signaling, producing anxiolytic effects without the sedation or dependence of benzodiazepines. Semax modulates BDNF and other neurotrophic signaling and has neuroprotective and dopaminergic/attention-related effects. The pairing is intended to deliver anxiety reduction (Selank) alongside cognitive enhancement and neuroprotection (Semax); the combined effect has not been formally characterized.
Why people research it
- Anxiety reduction without sedation (Selank)
- Cognitive performance, focus, and memory (Semax)
- Neuroprotection and recovery (Semax, incl. stroke)
- Combined 'calm + focus' nootropic use
Human evidence
No formal trials test the Selank + Semax combination. Individually, both have human data — but predominantly from Russian clinical studies: Selank has been compared with benzodiazepines for generalized anxiety, and Semax has been studied in acute ischemic stroke and cognition. These studies support each peptide's individual use within the Russian regulatory context but are generally smaller and less independently replicated than Western RCTs, and neither peptide is FDA-approved. The combination remains unstudied.
Animal / lab evidence
Both peptides have supportive animal literatures: Selank shows anxiolytic and immunomodulatory effects and BDNF changes in rodents, and Semax shows neuroprotective, neurotrophic, and cognition-related effects in animal models. No animal study evaluates the specific blend.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
Supports the Selank half of the stack for anxiety — a Russian trial of Selank by itself, not the combination.
Supports the Semax half of the stack via a stroke trial — Semax by itself, not paired with Selank.
History
Selank and Semax were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (Semax from ACTH(4-10); Selank from tuftsin) and entered Russian clinical use for anxiety and cognitive/neurological indications respectively. The nootropic community later paired them as a 'calm + focus' stack.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A Russian-developed heptapeptide analog of tuftsin studied as a nasal anxiolytic with minimal sedation in small clinical trials.
A Russian-developed ACTH(4-10) analog used intranasally and studied for cognitive performance and stroke recovery.
Delta sleep-inducing peptide, a nonapeptide studied for slow-wave sleep and stress modulation since the 1970s.